Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment

INTRODUCTION: Limited comparative effectiveness data for rituximab (RTX) versus natalizumab (NTZ), fingolimod (FTY), and dimethyl fumarate (DMF) for the treatment of multiple sclerosis (MS) exist. METHODS: Clinician‐reported data on patients prescribed RTX, NTZ, FTY, or DMF for the treatment of MS a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vollmer, Brandi L., Nair, Kavita, Sillau, Stefan, Corboy, John R., Vollmer, Timothy, Alvarez, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480919/
https://www.ncbi.nlm.nih.gov/pubmed/32767538
http://dx.doi.org/10.1002/acn3.51111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480919/
https://www.ncbi.nlm.nih.gov/pubmed/32767538
http://dx.doi.org/10.1002/acn3.51111

Ejemplares similares